FDC Documents Library
This article was originally published in The Gray Sheet
Executive Summary
Recent additions to the library include an FDA FDL-1warning letter to BioImagene about its PATHIAM image analysis software, the CDRH Office of Science FDL-2Annual Report for 2004, and the HHS FDL-3Inspector General Office letter to Senate Health Committee Chairman Mike Enzi (R-Wyo.) regarding four personal conduct allegations about FDA Commissioner-Nominee Lester Crawford. Sign up for a free twice-monthly email alert of new documents at 1http://www.fdceports.com/documentsalert and browse the Library at 2http://www.fdcreports.com/documents...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.